drugset / Trial / NCT01453140
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
Non-randomizedParallel-groupOpen-labelTreatment
Summary
In this study the investigators are proposing to treat patients with steroid-refractory Graft-versus-host Disease (GVHD) stabilization using IL-2 and azacitidine
Timeline
- Start
- 2011-08
- Primary completion
- 2012-03
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 10 mg | Subcutaneous |
| Subject | Cyclophosphamide | Other / unclassified | 4000 mg/m2 | Intravenous |
| Subject | Sirolimus | Small molecule | 2 mg | Oral |
| Subject | aldesleukin | Protein / enzyme biologic | 500000 iu | Subcutaneous |